Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia

NCT00664677 is registered in ClinicalTrials.gov with Erimos Pharmaceuticals as lead sponsor.

NCT NCT00664677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia
Lead sponsor
Erimos Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2007
Completion date
June 30, 2009
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia (all), acute myeloid leukemia (aml), adult t cell leukemia (atl), chronic lymphocytic leukemia (cll), chronic myeloid leukemia (cml-bp), chronic myelomonocytic leukemia (cmml), leukemias, myelodysplastic syndrome (mds)